Apellis Pharmaceuticals secured FDA approval for a supplemental new drug application expanding the use of its complement C3 inhibitor pegcetacoplan (Empaveli) to treat complement 3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis. Based on data from the phase III Valiant study, treatment demonstrated significant proteinuria reductions, stabilization of kidney function, and clearance of C3c staining in patients aged 12 and older. Empaveli, previously approved for paroxysmal nocturnal hemoglobinuria, offers a novel therapeutic option for these severe rare kidney diseases with an annual wholesale cost of approximately $505,000 per patient. The treatment showed a favorable safety and tolerability profile consistent with prior studies.